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Abstract
Background: Nearly all persons with Down syndrome will show pathology of Alzheimer’s disease in their 40s.
There is a critical need for studies to identify early biomarkers of these various pathological changes of Alzheimer’s
disease in the Down syndrome population and understand the relationship of these biomarkers to cognitive
symptoms in order to inform clinical trials. Although Alzheimer’s disease is often considered a disease of gray
matter, white matter degeneration has been documented during the preclinical stage of Alzheimer’s disease. The
current study examined the association between diffusion tensor imaging (DTI) measures of white matter
microstructure and episodic memory performance in 52 adults with Down syndrome.
Methods: Seventy (N = 70) participants (M = 40.13, SD = 7.77 years) received baseline scans as part of the
Neurodegeneration in Aging Down Syndrome (NiAD) study at two imaging facilities (36 at the University of
Wisconsin-Madison [UW-Madison] and 34 at the University of Pittsburgh Medical Center [UPMC]). All participants
had genetically confirmed trisomy 21. Fifty-two (N = 52) participants remained after QC. The DTI measures,
fractional anisotropy (FA) and mean diffusivity (MD), were calculated for each participant. A combined measure of
episodic memory was generated by summing the z-scores of (1) Free and Cued Recall test and (2) Rivermead
Behavioural Memory Test for Children Picture Recognition. The DTI data were projected onto a population-derived
FA skeleton and tract-based spatial statistics analysis was conducted using the FSL tool PALM to calculate Pearson’s
r values between FA and MD with episodic memory.
Results: A positive correlation of episodic memory with FA and a negative correlation of episodic memory and MD
in the major association white matter tracts were observed. Results were significant (p < 0.05) after correction for
chronological age, imaging site, and premorbid cognitive ability.
Conclusion: These findings suggest that white matter degeneration may be implicated in early episodic memory
declines prior to the onset of dementia in adults with Down syndrome. Further, our findings suggest a coupling of
episodic memory and white matter microstructure independent of chronological age.
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Background
Down syndrome (DS) is a genetic disorder caused by full
or partial trisomy 21 and is associated with a host of
physical and developmental problems including intellec-
tual disability, congenital heart disease, hypotonia, thy-
roid disorders, and sleep problems [1]. People with DS
also have several neuroanatomical brain differences from
typically developing populations, including brachyceph-
aly, ventriculomegaly, regional hypoplasia, and decreased
depth and reduced number of cerebral sulci [2]. DS is
also associated with an increased prevalence and early
onset of Alzheimer’s disease (AD) purportedly due to
the triplication of the amyloid precursor protein (APP)
gene, located on chromosome 21, which causes an over-
expression of amyloid-beta (Aβ). The extracellular accu-
mulation of Aβ plaques in the brain is one of the early
hallmarks of AD [3, 4]. The genetic linkage of increased
amyloid production in DS to increased AD risk is most
similar to the development of autosomal dominant AD
in non-DS populations, which account for only 1% of
AD cases as opposed to sporadic AD which accounts for
90% of total cases [5, 6]. Population-based studies sug-
gest that over half of adults with DS aged 55 years and
older receive a clinical AD diagnosis [7], with the life-
time risk of clinical AD in DS is approximately 90%
[8]. There is a critical need for natural history studies
to characterize early biomarkers of pathological
changes of Alzheimer’s disease in the Down syndrome
population and understand the relationship of these
biomarkers to cognitive declines in order to inform
clinical trials aimed at delaying or preventing AD in
this at-risk population [9].
Positron emission tomography (PET) imaging studies
have recently been used to characterize the early accu-
mulation of Aβ using the biomarker [11C] Pittsburgh
Compound-B (PiB) in adults with DS prior to onset of
clinical AD. These studies found that a subset of adults
with DS evidence marked Aβ accumulation (referred to
as PiB (+)), typically beginning in the striatum, by their
fourth decade of life with the majority being PiB (+) by
the middle of their fifth decade [10, 11]. These findings
indicate PET imaged Aβ accumulation occurs approxi-
mately 30 years earlier in the DS population as com-
pared to general population samples of adults without a
genetic risk for AD [10, 11].
Although AD is often considered a disease of gray
matter, white matter (WM) degeneration is evident in
adults diagnosed with clinical AD [12–14] and is also
observed during the preclinical stage (i.e., prior to onset
of clinical AD) and thought to result from the presence
of extracellular Aβ plaques followed by intracellular
neurofibrillary tangles of the protein tau [13–16]. Diffu-
sion tensor imaging (DTI) is a non-invasive magnetic
resonance imaging (MRI) technique that probes
microstructural differences in water diffusion properties
of biological tissue [4, 17–19] and has been used to
examine WM change associated with AD in both the DS
[9, 20] and non-DS populations [21, 22]. DTI measure-
ments include the mean diffusivity (MD), which is the
directionally averaged diffusivity and is sensitive to the
density of microstructural features; and the fractional
anisotropy (FA), which is a summary measure of the dir-
ectional variance of diffusivities and is often used as a
sensitive marker of WM microstructural changes [23].
Across studies of non-DS populations, adults with
clinical AD have been found to evidence increased MD
and decreased FA across multiple brain regions [12, 13,
16]. Moreover, WM integrity has been found to be asso-
ciated with cognitive decline and, more specifically, im-
paired episodic memory in non-demented adults from
non-DS populations [12, 15, 24]. For example, Nicholas
et al. (2020) found that increases in frontal MD across
time were associated with decreases in the ability to cor-
rectly recall words (i.e., free recall) in older adults with-
out AD [25]. Remy et al. (2015) found an association
between lower FA in the medial temporal lobe and
worse episodic memory in older adults without AD [26].
Similarly, Metzler-Baddeley et al. (2011) showed that
better WM integrity (increased MD and decreased FA)
in the fronto-temporal lobe was associated with better
episodic memory in older adults without AD [27]. Lastly,
Lockhart et al. (2012) found associations between lower
FA and worse episodic memory across younger and
older adults without AD throughout major association
fibers, including the superior longitudinal fasciculus, in-
ferior longitudinal fasciculus, the cingulum bundles, un-
cinate fasciculus, and thalamo-cortical projections [28].
In previous work from our own research group, we
found evidence that WM integrity may also be impacted
early on in AD in the DS population. Specifically, WM
integrity assessed using DTI was negatively associated
with PET Aβ using PiB in 65 non-demented adults with
DS. Adults with DS who were PiB (+) in the striatum
and/or neocortex had a higher level of WM insult than
did those without marked accumulation (PiB (−)). These
differences occurred for both MD and FA along the
major association tracts including superior longitudinal
fasciculus, inferior longitudinal fasciculus, the cingulum,
and uncinate fasciculus [29, 30]. Building on these find-
ings, it is now important to determine if WM integrity is
associated with declines in episodic memory, which also
occur early on in the transition to dementia in DS [24,
31, 32] and thus may be an informative biomarker of the
transition to the prodromal stage of AD in DS.
Given the large number of neuroanatomical abnormal-
ities in DS and the role of overproduction of Aβ in the
development of AD in DS, it is not clear if WM impair-
ments are involved early on in AD in DS and if DTI is a
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meaningful biomarker of WM differences linked to AD-
related cognitive change in this population. The goal of
the present study was to examine the association be-
tween DTI measured WM integrity and directly admin-
istered measures of episodic memory in 52 adults with
DS. We hypothesized that WM integrity, as character-
ized by FA and MD in the major association tracts (su-
perior longitudinal fasciculus, inferior longitudinal
fasciculus, the cingulum, and uncinate fasciculus), would
be associated with episodic memory performance. Ana-
lyses were conducted with and without controlling for
chronological age and premorbid cognitive ability. Given
that data come from two study sites, we also added a
control variable for site in analyses.
Methods
Participants
Consent or assent for study participation was obtained
from all adults with DS. Proxy consent was obtained
from caregivers who served as legal guardians. This
study was performed under the approval of the institu-
tional review boards for human subjects research. Sev-
enty (N = 70) participants (M = 40.13, SD = 7.77 years)
received baseline scans as part of the Neurodegeneration
in Aging Down Syndrome (NiAD) study at two imaging
facilities (36 at the University of Wisconsin-Madison
[UW-Madison] and 34 at the University of Pittsburgh
Medical Center [UPMC]). All participants had genetic-
ally confirmed trisomy 21. Subject demographic infor-
mation is presented in Table 1. Eighteen (n = 18)
participants were excluded due to excessive motion dur-
ing the DTI acquisition and removed from analyses. Of
the remaining participants, forty-six (n = 46) participants
were classified cognitively stable and three (n = 3) were
classified as having mild cognitive impairment (MCI)
and three (n = 3) were diagnosed with dementia. These
clinical status determinations were based on a case con-
sensus process that included at least three staff with
clinical expertise who were blind to MRI and PET im-
aging data. The following information was used in the
case consensus process: (a) medical/psychiatric history
and neurological exam; (b) caregiver-report of partici-
pant’s functioning and life events; (c) participant’s
adaptive skills on the Vineland Adaptive Behavior Scales
[33]; (d) caregiver-report of participant’s dementia symp-
toms on Dementia Questionnaire for People with Learn-
ing Disabilities [34] or Dementia Scale for Down
syndrome [35]; (e) participant’s profile on the Down
Syndrome Mental Status Examination [36], Develop-
mental Test of Visual-Motor Integration, 5th Edition
[37], Wechsler Intelligence Scale for Children [38], Block
Design and Haxby extension [35], and Developmental
NEuroPSYchological Assessment [39] Word Generation
Semantic Fluency. Informed consent was obtained prior
to data collection.
Diffusion tensor imaging
Magnetic resonance imaging (MRI) data were collected
on two 3.0T MRI scanners—a GE SIGNA 750 with an
8-channel head coil (UW-Madison) and a Siemens Mag-
netom Trio scanner with a 64-channel head coil
(UPMC). Diffusion-weighted imaging at both sites was
performed using a single-shell, diffusion-weighted spin
echo sequence (UW-Madison TR/TE = 7800/67 ms;
UPMC TR/TE = 7200/56 ms). The DWI protocol con-
sisted of either 7 (UPMC) or 6 (UW-Madison) non-
diffusion weighted (b0) images and diffusion weighted
images with a b value of 1000 s/mm2 in 48 non-collinear
directions. Additional imaging parameters consisted of
matrix size: and 116 × 116 with 80 slices, field of view:
23.2 × 23.2 × 16 cm3, and 2 mm slice thickness. Data
were processed using an in-house processing pipeline
utilizing tools from FSL [40], Mrtrix [41], and the DiPy
toolbox [42]. The diffusion-weighted data were corrected
for Gibbs’ ringing artifacts [43], Rician noise [44], and
eddy current distortions and head motion with outlier
replacement [45, 46]. A threshold of 10% or more of
slices replaced as outliers within a single diffusion
weighted image (DWI) was established as a criterion for
removal of a volume; however, no volumes exceeded this
threshold and no DWIs were removed. The diffusion
tensors were estimated using a robust estimator method,
RESTORE [47], and FA and MD maps subsequently
calculated.
All FA data in the study were aligned to a 2 mm iso-
tropic population-derived FA template using ANTs [48].
This template was constructed using amyloid negative
participants without MCI or AD. A medial surface skel-
eton was generated from the population-averaged FA
image. Each participant’s regional maximum FA data
were then projected onto this skeleton surface for voxel-
wise statistical analyses. The MD maps were likewise
spatially normalized and projected onto the FA skeleton
for analysis. The JHU white matter atlas labels [49] were
warped to the population-derived FA template using
ANTs [48].
Table 1 Subject demographic information







Females (%) 24 (46.15%) 0 (0%) 1 (33%)
Age in years (SD) 39.13 (7.77) 45.53 (3.59) 50.47 (5.26)
RSPPV (SD) 122.20 (34.63) 131.33 (24.58) 84.00 (17.78)
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Episodic memory composite measure
A composite score of episodic memory was calculated
based on two measures of episodic memory. The first
was the Free and Cued Recall test [50], a measure of ver-
bal episodic memory in which participants attempt to
learn and remember 12 pictures that are linked to cat-
egories (e.g., fruit). The Free and Cued Recall score is
the number of pictures recalled across three free trials
and three cued recall trials (i.e., category is given). The
second measure was the Rivermead Behavioural Memory
Test for Children Picture Recognition [51], a measure of
visual episodic memory obtained by determining if par-
ticipants are able to distinguish 10 pictures previously
presented from 10 pictures not previously seen after a
brief delay. The total score is the number correctly
recalled minus the number of false positives. These two
scores (Free and Cued Recall total and Rivermead Total)
were z-scored and summed to create the composite
measure used in the present study. The decision to use
this composite measure of episodic memory was based
on a principal component analysis involving five mea-
sures—Free and Cued Recall, Rivermead, Developmental
NEuroPSYchological Assessment (NEPSY) Visual Atten-
tion and Verbal Fluency tasks [39], and the Beery
Visual-Motor Integration [37]. The first principal com-
ponent was made up of the Free and Cued Recall, and
Rivermead scores and explained over 50% of the vari-
ance. Moreover, both measures have been shown to be
sensitive to other biomarkers of early AD in adults with
DS (e.g., Hartley et al. 2014).
Control variables
Sociodemographic variables and study site were included
in models to account for any effect on WM and episodic
memory. Chronological age in years was reported by
caregivers and is a useful control measure due to the
coupling of DTI measures with age [52]. Premorbid (i.e.,
prior to any concerns of AD) cognitive ability was
assessed using the Peabody Picture Vocabulary Test
[53], which assesses receptive language ability and has
been shown to be strongly associated with lifetime global
cognitive ability [54]. Imaging site was coded as Wiscon-
sin = 1 and Pittsburgh = 2 to allow us to control for any
differences in WM or episodic memory based on site.
The use of a site covariate was added to control for
scanner-related differences in the imaging protocol.
Statistical analyses
The distribution of variables and histograms of residuals
were used to assess use the normality of data and to
identify any outliers. Statistical analyses of the DTI data
were performed using the tract-based spatial statistics
pipeline in FSL [55, 56].
Pearson partial correlation analyses were performed
using a general linear model in FSL. The model con-
sisted of the episodic memory composite score, as well
as the following control variables—chronological age,
imaging site, and premorbid cognitive ability. Voxel-wise
partial correlation analysis of the tract-based spatial sta-
tistics (TBSS)-derived data and episodic memory com-
posite score (EMCS) using the above GLM was
performed using the permutation analysis of linear
models (PALM) package from FSL with 2D threshold-
free cluster enhancement (TFCE) optimization [57]. Cor-
rection for multiple comparisons was performed by con-
trolling for the family-wise error rate (FWER) [58].
Results
The episodic memory score was found to be near nor-
mal (kurtosis = 0.460) and with minimal skew (Pearson’s
mode skewness = − 1.270). Figure 1 shows the significant
negative correlations between the episodic memory
composite with MD. MD data are shown at a multiple
comparisons corrected significance of p < 0.05, with
additional covariates for imaging site, premorbid cogni-
tive ability, and chronological age. These covariates were
used to address variation between scanners (imaging
site), the understanding of the task (premorbid cognitive
ability), and the association of chronological age and
DTI measures. Significant associations were observed bi-
laterally throughout the superior and inferior association
fibers (see Table 2): superior longitudinal fasciculus (left:
r = − 0.399, p = 0.005 FWER corrected; right: r = −
0.444, p = 0.001 FWER corrected) as well as in the infer-
ior longitudinal fasciculus (left: r = − 0.504, p < 0.001
FWER corrected; right: r = − 0.452, p = 0.001 FWER
corrected). We also examined FA within these regions
and found significant associations bilaterally in the su-
perior longitudinal fasciculus (left: r = 0.280, p = 0.051
FWER corrected; right: r = 0.332, p = 0.020 FWER cor-
rected) as well as in the inferior longitudinal fasciculus
(left: r = 0.292, p = 0.042 FWER corrected; right: r =
0.372, p = 0.008 FWER corrected). All reported ROIs
were extracted using a mask of the significant voxels re-
ported in Fig. 1 within JHU WM atlas labels provided by
FSL [40, 49]. No significant negative correlations with
FA or positive associations with MD were observed.
Note that data are presented using the “tbss_fill” method
provided by FSL, and inflated regions reflect areas sig-
nificant at a multiple comparisons corrected p < 0.05. As
a follow-up analysis, we re-ran the above model after re-
moving the subjects with MCI or AD. The overall pat-
tern of results remained the same. The inferior
longitudinal fasciculus MD (left: r = − 0.451 (p = 0.002);
right: r = − 0.339 (p = 0.026)), superior longitudinal fas-
ciculus MD (right: r = − .305 (p = 0.047)), inferior longi-
tudinal fasciculus FA (left: r = 0.292 (p = 0.057); right: r
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= 0.407 (0.007)), and superior longitudinal fasciculus FA
(left: r = 0.28 (p = 0.076); right: r = 0.370 (p = 0.015)) re-
gions remained significantly associated with episodic
memory after correction for chronological age, site, and
premorbid cognitive ability. The global regions (FA: r =
0.201 (p = 0.196); MD: r = − 0.376 (p = 0.013)) had
trend-level associations with episodic memory after cor-
recting for chronological age, site, and premorbid cogni-
tive ability. Thus, the inclusion of the MCI and AD
participants did not appear to be driving findings.
Though voxelwise associations with FA did not sur-
vived at an α = 0.05 level, positive correlations between
FA and EMCS were observed at p < 0.08 corrected for
chronological age, imaging site, and premorbid cognitive
ability (see Supplementary Figure 1A). We also tested
the correlation between the composite measure and FA
only covarying for imaging site and premorbid cognitive
ability and observed diffuse regions of positive correl-
ation of the composite score with FA at p < 0.05 FWER
corrected (see Supplementary Figure 1B). The extent of
these regions throughout the association tracts is quite
similar to the extent observed for MD in Fig. 1.
Discussion
Adults with DS are genetically at-risk for AD with AD-
related pathophysiology nearly universally present by age
40 years [11]. There is a critical need within the DS field
for imaging studies that can describe the natural history
of early AD pathophysiology in DS and its link to cogni-
tive decline in order to inform clinical trials. To our
knowledge, the present study is the first to examine the
association between DTI measured WM integrity and
episodic memory in adults with DS.
Our findings revealed important associations between
WM integrity and episodic memory in the DS popula-
tion. FA was observed to be positively correlated with
episodic memory while MD was negatively correlated
with episodic memory. There were no significant nega-
tive associations between FA and episodic memory nor
positive associations between MD and episodic memory.
Associations between FA and MD (in positive and nega-
tive directions respectively) and worse performance on
measures of cognitive ability including episodic memory
have been reported on extensively in the aging literature
Fig. 1 Regions of significant negative correlation between EMCS and MD. Images arranged in right to left (R-L) and posterior to anterior (P-A).
Images overlaid on the population-derived FA skeleton (green) and the population-derived 2 mm FA template. Regions shown reflect areas with
Pearson’s r less than − 0.2. Data shown at a FWER corrected p < 0.05 with covariates for premorbid cognitive ability, imaging site, and age
Table 2 JHU atlas ROI comparisons of DTI parameters and the
episodic memory composite score (EMCS)
Pearson’s r (p value*)
Global FA and EMCS 0.341 (0.017)
Global MD and EMCS − 0.547 (< 0.001)
Left hemisphere Right hemisphere
ILF FA and EMCS 0.292 (0.042) 0.372 (0.008)
SLF FA and EMCS 0.280 (0.051) 0.332 (0.020)
ILF MD and EMCS − 0.504 (< 0.001) − 0.452 (0.001)
SLF MD and EMCS − 0.399 (0.005) − 0.444 (0.001)
*Corrected for family-wise error rate, imaging site, chronological age, and
premorbid cognitive ability
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on non-DS populations [26–28]. Further, decreased FA
and/or increased MD have been reported in adults with-
out DS who are exhibiting MCI and/or AD relative to
healthy controls [20, 59]. Our findings serve as a bridge
between the cognitive insights of bridge between the
previous reports of the central role of episodic memory
declines in AD in DS [60–62] with the body of DS DTI
literature [9, 20, 59] showing that disruptions of episodic
memory in early cognitive decline may arise from the
degeneration of association white matter pathways be-
tween regions of the brain, particularly frontal, medial-
temporal, and parietal lobe areas. Further, our results
highlight the clinical potential of DTI, particularly MD,
as a non-invasive biomarker to detect early cytoarchitec-
tural changes that may be associated with AD in adults
with DS. If DTI continues to emerge as a useful bio-
marker of AD-related cognitive change in future studies
that are larger and longitudinal, this biomarker has the
potential to be informative for participant selection and
outcome tracking in AD clinical trials in DS. Indeed, ef-
forts to launch large AD intervention trials in DS are
already underway, yet currently involve a limited array
of established AD biomarkers. DTI is already an estab-
lished biomarker in pediatric populations and is used to
detect both gray matter and white matter changes aris-
ing from neurodevelopmental conditions such as
Gaucher’s disease [63] and Crigler-Najjar Syndrome
[64], illustrating the promise of DTI as a clinically rele-
vant biomarker in rare genetic disorders, such as DS.
There is a tight linkage between chronological age and
DTI indices which may have impacted our results [52,
65]. Indeed, in the current sample, chronological age
was correlated with FA in major tracts at r = − 0.482 (p
< 0.001). However, the FA and MD associations with
episodic memory remained even after controlling for
chronological age. There is also a coupling of episodic
memory performance with premorbid cognitive ability (r
= 0.508, p < 0.001) and decline with chronological age (r
= − 0.491, p < 0.001) in our sample. In controlling for
chronological age and premorbid cognitive ability, our
findings represent the episodic memory changes above
and beyond these other effects. Our results suggest a
coupling of white matter cytoarchitecture and episodic
memory that is independent of chronological age. Fur-
ther study is needed to understand other factors that
may impact this relation.
Conclusion
The present study had both strengths and limitations.
To our knowledge, this is the largest study examining
the association between DTI measures of WM integrity
and cognitive functioning in the DS population and is
the first to show that WM impairment may be impli-
cated in early declines in episodic memory in DS. There
were also limitations to the present study. First, adults
with DS are a difficult population to image, due to in-
creased subject motion in the scanner. Indeed, motion
led to the rejection of several subjects due to imaging ar-
tifacts. Second, larger cohorts and longitudinal studies
are needed to tease apart the time-ordered direction of
effects of WM impairment and episodic memory with
age, as this is not clear given the cross-sectional nature
of the present study. Finally, future studies should in-
clude biomarkers of Aβ and tau in addition to WM in-
tegrity and evaluate whether WM impairment has an
effect on cognitive functioning that is independent from
these other aspects of AD pathophysiology.
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